Novo shares tumble after unveiling expanded growth strategy at London capital markets day
Novo's stock slipped on Monday following the launch of a refreshed strategy that emphasizes its core diabetes and obesity business while targeting new areas such as liver and cardiovascular disease.
During a London capital markets day, Novo's chief executive Mike Doustdar presented an updated corporate strategy that will reinforce the firm's diabetes and obesity franchises while expanding into liver and cardiovascular disease treatments. The plan includes an ambition to launch a minimum of five multi-blockbuster products—drugs generating several billion dollars in annual sales—by 2030. Novo also aims to generate significant revenue from its pipeline of yet-to-market candidates.
Investment strategist Jacob Pedersen of Middelfart Sparekasse commented that the objectives lack a dramatic "wow" factor and omit any acquisition plans, though they signal sustained high-speed R&D activity and a stable profit-margin projection for upcoming years. Doustdar has led Novo for just over a year.
Why it matters
Investors and patients watch Novo's strategic shifts because they affect future drug availability and the company's market performance.
In this story
